Advent, CVC Capital seeking inVentiv buy weeks before IPO: Reuters

Should it stay or should it IPO? That’s the question facing inVentiv owner Thomas H. Lee Partners as it weighs up potential bids from two buyout firms--while also mulling over going public.

This is according to sources talking to Reuters, who say Advent International and CVC Capital Partners “have made offers to acquire” inVentiv Group Holdings, the parent company of biopharma services provider inVentiv Health.

But a SEC report filed in April by inVentiv shows it is looking to gun for an IPO, with the company having a valuation of “over $4 billion” including debt, people familiar with the matter told the news wire service. The company was not commenting on the story.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

A decision, the sources said, will be made by next week, and if an IPO is chosen, the company will look to go public next month. An IPO of $100 million was first spoken of, though analysts believe this could be bumped up to $500 million.

Last year, InVentiv reported net revenue of $2 billion, up 10% from the before-year period.

- check out the Reuters story

Related Article:
InVentiv to go public, hopes to raise $500M

Read more on

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.